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This review focuses on the factors that regulate the proliferation of pancreatic islet j&cells in vitro, and in particular on the intracellular pathways 
that convey the mitogenic signal into a proliferative response. Substances a  diverse as nulrients, polypcptides, cytokines, adrenergic agents, lithium, 
phorbol esters nnd cyclic AMP analogs are all able to stimulalc or inhibit@cll proliferation in a time- and concentration-dependent manner. The 
evidence for involvement of cyclic AMP, cyclic GMP, protein kinasc C, inositol polyphosphates. GTP-binding proteins. polyamincsand oncogcnes 
is reviewed. 
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1. INTRODUCTION 
The pancreatic B-cell has a limited proliferative po- 
tential, and the production of new @cells by division 
normally does not exceed 3% per day, a figure that 
rapidly declines with increasing age [l]. Early investiga- 
tors demonstrated that growth of the islet organ could 
be stimulated in vivo by diets rich in carbohydrates [2] 
or in a genetic animal model for diabetes mellitus, viz. 
the obese-hyperglycemic mouse [3]. Most studies in re- 
cent years aiming at elucidating factors controlling the 
proliferation of j&cells in vitro have utilized pancreatic 
islets isolated from fetal or neonatal rats containing a 
high fraction of rapidly growingb-cells, and rely heavily 
on the use of [3H]thymidine incorporation techniques as 
measures of /?-cell proliferation [l]. 
Knowledge of the mechanisms that govern the prolif- 
erative capacity of the healthy @cell may be exploited 
to maximize the growth potential of pancreatic islet 
grafts prior to transplantation i to diabetic patients and 
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thus improve the fate of the graft. Given the fact that 
virtually all forms of diabetes mellitus are characterized 
by an insufficient extent of p-cell replication needed to 
compensate for the loss or dysfunction of j%cells occur- 
ring in diabetes [l], elucidation of the growth-regulating 
pathways might also give rise to novel pharmacological 
means of expanding the remaining endogenous p-cell 
population. It should be recognized that the techniques 
used to assess /?-cell proliferation, i.e. [3H]thymidine la- 
beling or bromodeoxyuridine incorporation into DNA, 
have several shortcomings, including artefactual 
changes in incorporation due to alterations in isotope 
uptake, metabolism and specific activity [11. The regula- 
tion of/3-cell replication by extracellular factors and by 
intracellular signaling systems is summarized in Fig. 1. 
2. NUTRIENTS 
D-Glucose is a cardinal stimulator of /&ell prolifera- 
tion in adult and late fetal life, whereas the sugar seems 
to be inactive at earlier stages of development [4]. Me- 
tabolism of the carbohydrate appears essential, because 
t-glucose, D-fructose and 3-O-methylglucose are inac- 
tive as j&cell mitogens, and mannoheptulose, an inhibi- 
tor of glucose phosphorylation, suppresses /%cell 
growth [5,6]. When fetal rat islets were maintained in 
tissue culture at widely different glucose soncentrations. 
it was found that the cell cycle proceeded at constant 
rate irrespective of ambient glucose concentration [q. 
This gave rise to the proposal 
p-ceil repiication by increasing 
entering the cell cycle. 
that glucose enhances 
the nti’bef Of i;*lia 
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Fig. I, Summary of the mechanisms that regulnte pancreatic /%ccll 
proliferation in vitro. This cartoon depicts cxtraccllular Ihctors that 
stimulate (left side) or inhibit (right side)p-cell replication. Inside the 
cell difl’crcnt signal transduction pathways are schematically shown. 
Arrows indicate stimulatory (+) or inhibitory (-) uctions on cell pro- 
!iferation. ‘0’ denotes no effect, whereas ‘?’ denotes uncertain cll’ect. 
AC, adenylyl cyclasc; a-R, a-adrencrgic receptor; ATP, adenosine 
trisphosphate; CAMP, adenosinc-3’,5’-cyclic monophosphate; cGMP, 
guanosineS’,!?-cyclic monophosphate; Clon, clonidine: DBI, diaze- 
pam binding inhibitor; GH, growth hormone; Gi, inhibitory GTP- 
binding protein; IFN. y-interferon: IGF-I, insulin-like growth factor 
I; IL-Ip, interleukin-lp; IP3, inositol trisphosphate; PDGF. platelct- 
derived growth factor; Phe, phenylephrine; PKC, protein kinasc C; 
PTX, pertussis toxin; TGF-j. transforming rowth factor/?. The z- 
adrenergic agonists clonidine and phenylephrine inhibit/-cell rcplicu- 
tion by suppressing CAMP synthesis. This effect occurs as a result of 
iaterfersncc with an inhibitory GTP-binding protein that couples the 
receptor and adenylyl cyclase. an cl%ct that is prevented by pertussis 
toxin. See text for further details. 
Amino acids are also able to stimulate P-cell replica- 
tion, and it appears as if in early fetal life they are more 
important than is glucose in this respect [4]. Amino 
acids, and human amniotic fluid, were recently also 
identified as potent stimulators of cell proliferation in 
adult mouse islets [S]. Interestingly, in children with 
certain inborn errors of amino acid metabolism leading 
to hyperaminoacidemia, anexpansion of the pancreatic 
/?-cell fraction has been noted, strongly suggesting that 
the stimulation of /?-cell replication observed in vitro 
bears clinical significance [9]. 
3. POLYPEPTIDES 
Among the large number of protein hormones exist- 
ing, growth hormone (GM) and ihc biologically related 
lactogenic peptides prolactin and placental lactogen 
have been extensively investigated with regard to effects 
on /?-cell proliferation. Thus, GH has been reported to 
stimulate the in vitro replication of fetal [IO], neonatal 
[11,12] and adult [12,13] rat ,&cells. In most of these 
studies there was also a stimulatory effect of GH on the 
insulin content and/or secretion and the majority of 
effects were mimicked by prolactin and placental acto- 
gen. It should be noted that the doses of hormones used 
in the referred studies are several orders of magnitude 
greater than those encountered in vivo, which sheds 
86 
some doubt on the physiological significance of the ob- 
served effects. On the other hand, it should be borne in 
mind that in acromegaly and in neonates, as high serum 
levels of GH as 0.2 &/ml have been reported [I]. Also 
during pregnancy, levels of prolactin approach 0.2 ,~ugl 
ml and those of placental lactogen 8 ,ug/ml [11. It is thus 
conceivable that the elevated serum levels of these 
hormones may contribute to the expansion of the P-cell 
mass that occurs during these states by direct interac- 
tion with the ,&cell. Because GH in many other tissues 
appears to elicit its biological activities by inducing local 
production of insulin-like growth factors (IGFs) in tar- 
get cells [l4], the issue of whether a similar paracrine 
pathway operates also in islets has been addressed. 
Thus, Swenne et al. [lo] and Swenne and Mill [13] re- 
ported that in both fetal and adult rat islets GM, but not 
glucose, stimulated release of IGF-I from islets and that 
inclusion of a monoclonal antibody to IGF-1 partially 
counteracted the mitogenicity of GH. These results, and 
the fmdings that exogenous IGF-1 stimulates p-cell rep- 
lication and that ,8-cells possess high-affinity IGF-I re- 
ceptors [ 151, led Swennc et al. [10,13] to propose that 
IGF-I, produced by islet cells, participates in a parac- 
rine loop that mediates part of GH’s mitogenicity in 
p-cells. This view has, however, been challenged by oth- 
ers [16], who failed to detect an increase in IGF-I secre- 
tion from neonatal rat islets after GH exposure. In addi- 
tion, Hansson and associates [17] were unable to see a 
decrease in pancreatic IGF-I mRNA after alloxan ad- 
ministration, and suggested that IGF-I immunoreactiv- 
ity seen in al;ociation with p-cells represents peptide 
that has either been internalized or receptor-bound. 
This latter interpretation was also proposed by Nielsen 
et al. [18], who found a very modest mitogenicity of 
IGF-1 that did not augment he powerful response to 
GH. A recent preliminary report showed that GH does 
not affect expression of c-fos in RINSAH insulinoma 
cells, whereas a stimulatory effect on the expression of 
this oncogene was noted after exposure to the cyclic 
AMP-raising agent forskolin [19]. 
Other polypeptides investigated for possible effects 
on ,&cell proliferation include cytokines which are pro- 
duced by various immune cells that are known to infil- 
trate the pancreatic islets early in the course of juvenile 
diabetes mellitus [20]. While interleukin- lp was found 
to suppress islet cell proliferation in adult mice and rats 
[21,22], a bimodal pattern was noted in fetal rat islets 
[23], Thus, during the initial 24 h interleukin-l/3 sup- 
pressed &cell growth, an effect that waned by 2 days 
and was turned into a potent mitogenic response by 3 
days of exposure [23]. Interestingly, interleukin-1,8 has 
been found to increase the expression of c-fis in insulin- 
producing cells [24] and to stimulate the activity of a 
tyrosine kinase [25]. Interferon-y caused a much more 
moderate enhancement of@ell replication from day 1 
and onwards while at the same time inhibiting insulin 
secretion [23]. Interleukin-6, tumor necrosis factor a, 
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and interferon-a were virtually inactive in this system 
[231. 
Naturally, since the islets are comprised of a hetero- 
genous cell population, there is a risk of picking up 
changes in proliferation of islet cells other than the j?- 
cells. In particular, contamination of rapidly growing 
mesenchymal cells must be excluded, since this might 
well obscure changes in P-cell DNA synthesis. To this 
end, electron microscopical analyses have shown that 
no fibroblast-like or acinar cells could be detected in 
cultured fetal islets, which were found to consist of 
r90% P-cells [lo]. In addition, we and others have re- 
cently shown that these islets do not increase their rate 
of DNA synthesis in response to classical fibroblast 
mitogens uch as EGF, TGF-o: or PDFG; whereas well- 
known stimulators of p-cell replication (i.e. glucose or 
GH) were effective in this respect [26,27]. These com- 
bined findings support the notion that most results re- 
ported on fetal islets in this review reflect alterations in 
B-cell DNA synthesis; however, it is advisable that, at 
least when working with adult islets that contain =70- 
80% p-cells, to identify the DNA-synthesizing cells by 
immunostaining. 
4. POLYAM IN ES 
WhenP-cell proliferation was stimulated in vitro by 
glucose, amino acids, GM, PDGF I- IGF-I or lithium, 
it was found that these substances also elevated the islet 
contents of polyamines [8.26,27]. molecules known in 
other tissues to regulate cell replication [28]. When the 
increases in polyamines were prevented by addition of 
selective polyamine synthesis inhibitors together with 
the mitogenic factors, the elevated rates of p-cell DNA 
synthesis persisted, or were in some cases even ampli- 
fied. However, the polyamine content of cell nuclei was 
not affected by the inhibitors, suggesting that mainte- 
nance of polyamines in the nucleus may be an event 
sufficient to permit a mitotic signal to be translated into 
a proliferative response. In adult P-cells the bulk of 
polyamines have been shown by immunochemical stain- 
ing to be localized in insulin secretory granules [28a]. 
However, in fetal,&ceIls as much as 20-25% seem to be 
associated with the nucleus. It is not known whether 
changes in cytosolic polyamines may be transduced into 
the nucleus by the polyamine-dependent casein-kinase 
II. See Fig. 2 for a view ofj-cell polyamine metabolism. 
Transforming growth factor p (TGF-,!?) is a widely 
distributed polypeptide, which recently was reported to 
inhibit the mitogenic response of @ells to a high glu- 
cose concentration, but not to GH [29]. This effect by 
the peptide likely resulted from interference with signal 
transduction beyond the step of polyamine synthesis, 
because the islet polyamine content was not affected by 
TGF-,fX Among other regulators of /hAi replication, 
we recently identified pancreastatin and diazepam bind- 
ing inhibitor (DBI) as inhibitors of this process [30]. 
DFMO 
NUCLEUS 
Fig. 2. Polyaminc mctaboliam in pancrcatic~-cells. Ornithine isdeear- 
boxylated to yiehi the diaminc putrcscinc in a reaction catalyzed by 
ornithinc decarboxylase, the overall rate-regulating enzyme in this 
pathway. S-Adenosylmcthioninc decarboaylase catalyzes the forma- 
tion ordecarboxylated S-adenosylmcthioninc, which scrvycs as adonor 
or aminopropyl moieties used in the further synthesis of spcrmidine 
and spermine. In the top, a number ofstimulators of&xll prolircra- 
tion and polyaminc synthesis are shown. ‘4’ dcnotcs stimulation. 
Compounds that inhibit (-) cnrymc activity are DFMO. which s)xcif- 
ically and irreversibly inactivate ornithinc dcetarboxylasc, and EGBG 
which is highly selective S-adenosyhncthionine decarboxylusc inhibi- 
tor. Thcsc inhibitors dccrcasc the cytosolic polyamine content and 
appear to cause a translocation oramines into the nucleus; this latter 
cvcnt that may explain why jhcell prolikration is not dccreascd after 
treatment with DFMO and EGBG. DFMO, ot_s-diRuoromcthylor- 
nithinc; EGBG. ethylglyoxal bis(guanylhydratone); GH, growth 
hormone; IGF-1, insulin-like growth factor I; PDGF. platcletderivcd 
growth factor. 
Pancreastatin, but not DDI, also iGwcred the islet con- 
tent of polyamines, an event possibly contributing to the 
antiproliferative action of this peptide. Since both pan- 
creastatin and DBI are produced by islet cells, it is 
conceivable that they might function as paracrine inhib- 
itors ofj3-cell replication in vivo. 
5. CYCLlC NUCLEOTIDES AND GTP-BINDING 
PROTEINS 
Among many early events taking place in response to 
mitogenic stimulation in various cell systems are in- 
creases in cyclic AMP synthesis, protein kinase C acti- 
vation, inositol polyphosphate generation and calcium 
influx. These events occur also in the /?-cell in response 
to secretagogic stimulation, but it is not known whether 
these PI ocesses play any role in /I-cell replication. 
In search for intracellular mechanisms operational in 
transducing the mitogenic message of glucose, a great 
de:! of interest !1as been foctised on the role of cyclic 
AMP in this context [l]. Glucose is known to increase 
cyclic AMP in islets, but attempts to utilize various 
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cyclic AMP analogs as pharmacological probes have 
resulted in a large body of conflicting results concerning 
the role of cyclic AMP in ,&ceJl proliferation. Thus, 
addition of the phosphodiesterase inhibitor theophyl- 
line was found to decrease replication of neonatal ,t?- 
cells in culture [31]. On the other hand, addition of 
another phosphodiesterasc inhibitor, viz. isobutyl-l- 
methylxanthine produced bimodal effects inasmuch as 
low concentrations of the drug stimulated [31,32], and 
high concentrations suppressed ,&cell growth [32]. S-Br- 
cyclic AMP reportedly enhanced p-cell replication [32], 
while dibutyryl-cyclic AMP was found either to stimu- 
late [32,33] or inhibit [34)/?-cell replication. In addition, 
the adenylyl cyclase activator forskolin has been re- 
ported to stimulate this process [35,36]. 
All these results should be viewed with a great deal 
of caution, because none of the analogs used interferes 
specifically with cyclic AMP metabolism. For instance, 
for each cyclic AMP molecule split off once dibutyryl- 
cyclic AMP has entered the cell, two butyryl moities are 
liberated. Since butyrate is known to afhect many cellu- 
lar functions of its own, including DNA synthesis [37], 
the true role of cyclic AMP in ,&cell replication might 
be severely obscured by use of dibutyryl-cyclic AMP. 
Indeed, we have found that high concentrations of so- 
dium butyrate causes a marked inhibition of /?-cell 
growth and also blocks the mitogenic response to the 
cyclic AMP-raising agent forskolin [36]. 
In two recent studies it was shown that proliferation 
(and insulin secretion) of fetal rat /J-cells could be signif- 
icantly suppressed by a-adrenergic stimulation (using 
the a,-agonist phenylephrine and the a?-agonist cloni- 
dine) and by the cytokine interleukin-l/3 [38,39]. In both 
cases islet cyclic AMP content was found to be lowered. 
as well. Addition of pertussis toxin, which alleviates 
adenylyl cyclase from an inhibitory constraint by ADP- 
ribosylating GTP-binding proteins, resulted in an in- 
crease in islet cyclic AMP and stimulation of /?-cell pro- 
liferation and insulin secretion; these effets were mim- 
icked by the membrane-permeant stimulatory cyclic 
AMP analog Sp-cAMP[S] [38,39]. When the a-adrener- 
gic agonists were given together with Sp-cAMP[S] or to 
pertussis toxin-pretreated islets, the suppressed ,&cell 
proliferation and insulin secretion were partially pre- 
vented, suggesting that a-adrenergic stimulation ;e- 
presses p-cell growth and hormone release in part by 
interfering with GTP-binding proteins that connect cell 
surface receptors to adenylyl cyclase [3S]. In contrast, 
no such protection was imposed by pertussis toxin or 
Sp-cAMP[S] against the inhibitory actions of inter- 
leukin-lp [39]; nor was the suppression of RINmSF 
insulinoma cell proliferation and insulin secretion 
evoked by interleukin-I/?, interferon-y, or interferon-a 
affected by pertussis toxin pretreatment [40]. In their 
entirety, the findings referred to above point to a stimu- 
latory, rather than inhibitory, role for cyclic AMP in 
regulation of b-cell growth. 
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The guanylate cyclase activator atrial natriuretic pep- 
tide, known to increase /?-cell cyclic GMP levels [41], or 
a membrane permeant cGMP analog failed to affect 
/%cell growth under basal and stimulatory sonditions, 
suggesting that cyclic GMP has no modulatory role in 
this process 1361, although glucose has been reported to 
increase islet content of this nucleotide [42]. 
6. PROTEIN KINASE C AND INOSlTOL POLY- 
PHOSPHATES 
Some P-cell mitogens, e.g. glucose and polypeptide 
growth factors, are known in p-cells or other tissues to 
enhance thr activity of protein kinase C and to stimulate 
synthesis of inositol polyphosphates from plasma mem- 
brane phospholipids [43,44]. Protein kinase C is a phos- 
pholipid- and Ca’*-dependent enzyme that is activated 
by diacylglycerol which is formed during agonist-in- 
duced polyphosphoinositide hydrolysis [LES], an event 
that occurs early in transduction of the mitogenic signal 
[44]. Protein kinase C activity is subject o stimulation 
not only by the endogenous compound diacylglycerol, 
but also by tumor promoting phorbol esters, such as 
12”U-tetradecanoylphorbol I 3-acetate (TPA, [45]). 
Exposure of fetal islets to low concentrations ofTPA, 
considered specific for C-kinase activation, led to a 
stimulation of/?-cell replication, the magnitude of which 
resembled that of glucose or GH [46]. TPA also elevated 
the islet polyamine content, but when this increase was 
precluded by use of enzyme-directed inhibitors of pol- 
yamine synthesis, the mitogenic response persisted. It 
should be noted, however, that in another system of islet 
cell preparations, this mitogenic action ofTPA was not 
observed [35]. 
When protein kinase C was down-regulated by pro- 
longed exposure to high concentrations ofTPA prior to 
addition of high glucose, GH or forskolin, the mito- 
genie and secretory responses to these agents persisted 
[36]. On the other hand, inclusion of H-7, an inhibitor 
of protein kinase C and cyclic AMP-dependent kinases, 
caused a marked inhibition of proliferative activity but 
it is difficult to tell whether this is due to actions pre- 
dominantly on the cyclic AMP- or the C-kinase system 
[461- 
Cellular inositol polyphosphate l vels can also be in- 
creased in a way different from stimulation of their 
synthesis, viz. by preventing their degradation. One 
compound capable OF preventing inositol polyphos- 
phate breakdown is lithium, which has been shown to 
elevate a number of inositol polyphosphate species in 
p-cells and also is a /?-cell mitogen [27]. In particular, 
inositol-I ,3,4-trisphosphate was increased by lithium, 
and has also been reported to be elevated by the potent 
stimulator of/J-cell growth, glucose. It is therefore con- 
ceivable that this inositoi poiyphoaphate or others, pos- 
sibly due to their ability of mobilizing intracellular Ca’+, 
is important in mediating the mitogenicity of certain 
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/3-cell growth factors. It is clear, however, that this area 
is in need of further investigations. 
7. CONCLUSIONS 
Pancreatic /?-cell proliferation can be stimulated in 
vitro by glucose, amino acids, GH, PDGF + !GF-I, 
lithium, interferon-y or interlcukin-lb. Interleukin-l/J, 
however, caused an initial inhibition of j%cell growth 
that occurred independent of interaction with pertussis 
toxin-sensitive GTP-binding proteins or the cyclic AMP 
signaling pathway. TGF-j? and the islet-produced pep- 
tides pancreastatin and diazepam binding inhibitor can 
function as inhibitors of,&cell growth depending on the 
ambient glucose concentration. a-Adrenergic agonists 
were found to suppress P-cell proliferation in part by 
interference with GTP-binding protein(s) connected to 
adenylyl cyclase. Many of the mitogenic factors caused 
an increase in the islet content of polyamines; however, 
when this increase was blocked by enzyme-directed in- 
hibitors the mitogenicity of these compounds persisted. 
Specific pharmacological ctivation of protein kinase C 
or cyclic AMP synthesis increases j-cell DNA synthesis. 
8. FUTURE PROSPECTS 
While most. recent studies on the regulation of j-cell 
replication have focused on various biochemical path- 
ways, future research efforts should take advantage of 
molecular biology techniques in order to elucidate in 
detail the mechanisms that govern /I-cell replication. 
Such approaches would include studies of the expand- 
ing family of proto-oncogenes, encompassing analysis 
of changes in their expression after mitogenic stimula- 
tion, clarification of the functional significance of a par- 
ticular proto-oncogene by addition of specific antisense 
oligonucleotides and by overexpression of the oncogenc 
in isolated islets or in transgenic animal models. Similar 
approaches may be used to investigate the role of osher 
regulatory molecules, e.g. isozymes of phospholipases, 
protein kinases/phosphatases, polynmine synthesizing 
enzymes, phosphatidyl kinasc and various tyrosine ki- 
nases. Other biochemical systems that need to be inves- 
tigated include Ca?’ fluxes, signaling through S-HT, 
GABAergic and dopaminergic receptors and the inosi- 
to1 polyphosphate system. 
/Ickno~rl~d~e/rrertrs: Own work rei’crnd to herein was supported finan- 
cially by the Swedish Medical Research Council (I 2X- IOQ), the Cancer 
Foundation, Funds of the Karolinska Institute. the Medical Faculty 
at Uppsala University, the Swedish Diabetes Association, the Swedish 
Society of’ Medicine, the Clas Groschinsky Memorial Foundation, the 
Welye Axson Johnson Foundation, the Torstcn and Ragnar SBdcr- 
berg Foundations, the Hoechst Diabetes Foundation, the Nordic In- 
sulin Fund, the Family Ernrors Fund, the Royal Swedish Academy 
of’ Sciences. the Lars Hiena Memorial Foundation, and the Swedish 
Society for Medical Research. 
REFERENCES 
Hcllerstram. C., Andersson. A., Swcnne, I., Welsh, M.. Webb, 
N. and Sjbholm, A., in: Pathogcncsis of Non-Insulin Dependent 
Diabetes Mellitus (S. EfcndiC and V. Grill. Eds.) Raven Press, 
New York, 1988. pp. 79-91. 
Tejning, S. (1947) Acta Med. Stand. 12% (Suppl. 198) l-154. 
Westman. S. (1968) Diabctologia 4, 141-149. 
Swcnnc, I., Bone, A.J.. Howell, S.L. and Hellerstr0m. C. (1980) 
Diabetes 29, 686-692. 
King, D.L. and Chick, W.L. (1976) Endocrinology 99, 1003- 
1007. 
King, D.L., Kitchen, DC. and Chick, W.L. (1978) Endocrinol- 
ogy 103, 1321-1329. 
Swcnne, I. (1982) Diabetes 31.754-760. 
Dunger, A.-M., Sj6holm. A. and Eizirik, D.L. (1990) Pancreas 
5. 639646. 
Milner, R.D.G. and Wirdnam, P.K. (1982) Pediatr. Res. 16.213- 
216. 
Swennc. I., Hill. D.J.. Strain, A.J. and Milncr. R.D.G. (1987) 
Diabetes 36, 288-294. 
Nielsen, J.H. (1989) Exp. Clin. Endocrinol. 93, 277-285. 
Brelje, T.C.. Allsirc, P., Hegre. 0. and Sorenson, R&L. (1989) 
Endocrinology 125, 2392-2399. 
Swcnnc, 1. and Hill, D.J. (1989) Dittbctologia 32, 191-197. 
Milner, R.D.G. and Hill. D.J. (1984) Clin. Endocrinol. 21.41% 
433. 
VanSchravendijk, C.F.H,, Foricrs, A.. Van den Bmnde, J.L. and 
Pipeleers, D.G. (1987) Endocrinology I21. 178&1788. 
[I61 Romanus. J.A., Rabinovitch, A. and Rechler, M.M. (1985) Dia- 
betes 34.696702. 
[17] Hansson. H.A.. Edwall, D., LBwenodlcr, B.. Nordstedt. Ci., 
Palacus, P. and Skottner, A. (1988) Acta Phys. Stand. 132,569- 
576. 
[IS] Nielsen, J.H., Moller-Petersen, L. and Pedcrscn. E.E. (1988) Di- 
abctologia 31, 52GA (abstract). 
[I91 Petersen. E.D., Billcstrup, N. and Nielsen, J.H. (1992) J. Cell. 
Biochcm. Suppl. I6B. 242. 
[20] Sandlcr, S.. Bendlzen, K.. Eizirik. D.L.. Svcnsson, C., StrandelI. 
E., Welsh. M. and Welsh. N. (1991) Autoimmunity 10, 241-253. 
[2L] Soulhem, C., Schulstur. D. and Green, I.C. (1990) Biochcm. J. 
773 ‘43-245. * -I _ 
[22] Eizirik, D.L., W&h. M., Stmndcll, E., Welsh, N. and Sandlcr. 
S. (1991) Endocrinology 127, 22QO-22Q7. 
[23] Sjbholm, A. (1992) Am. J. Physiol., in press. 
[24] Hughes, J.H., Watson, M.A., Easom, R.A., Turk, J. and Mc- 
Daniel, M.L. (1990) FEBS Lat. 26G, 33-36. 
[2S] Martin, M., Love& D.H.. Szamel, M. and Resch. K. (1989) Eur. 
1. fliochem. 180.343-350. 
[28] Pea, A.E. (1986) Biochcm. J. 234, 249-262. 
[28a] Hougaard, D.M., Nielsen, J.H. and Larsson, L.-I. (1986) Bio- 
chcm. J. 238.43-47. 
t291 
[301 
[311 
134 
1331 
::; 
Sjbholm, A. gnd Hellcrstram, C. (1991) Am. J. Physiol. 260, 
C1046-ClO51. 
SjBholm, A., Funakoshi. A., Ebndif. S.. t%tenson. C.-G. and 
Hcllerstrdm, C. (1991) Endocrinology 128, 3277-3282. 
Nielsen, J.H. (1985) Biomed. Biochim. Acta 44. 161-166. 
Rabinovilch, A., Blondcl. B.. Murray, T. and Mintz, D.H. (1980) 
J. Clin. Invest. 66, 1065-1071. 
Logothetopoulos, J.. Vnliquette. N. and Cvct. D. (1983) Diabetes 
32, 1172-t 176. 
Swennc, 1. (1982) Biosci. Rep. 2, 867-872. 
Mourmeaux. J L.. Rcmacle. C. and Hcnquin. J.C. (1989) Endo- 
crinology 125, 2636-2644. 
[26] Sjtiho!m, A., Welsh, N.. Sundler, S. and Hrllcrstrtim. C. (1990) 
Am. J. Ph siol. 259, C828C833. 
[27] Sjbholm, x ,, Welsh. N. and Hclleratr6m, C. (1892) Am. J. Phys- 
iol. 2G2, C391-C395. 
Volume 3 1 I, number 2 FEES LETTERS October 1992 
[36] Sjtiholm, A. (1902) J. Cell. Biochcm. Suppl. IGB, 331, 
[37] Hagopian. H.K.. Riggs, M.G., Swartz, L.A. und Ingram. V.M. 
(1977) Cell 12. 555-861. 
[38] SjBholm, A. (1991) Biochem. Biophys. Rcs. Commun. 180, IX!- 
155. 
[39] Sjtrholm, A. (1991) FEDS Leit. 789. 249-252. 
[40] Sj6holm, A. (1991) Immunol. Lett. 30, 81-G. 
[4l] Vcrspohl. E,J. and Amman. H.P.T. (1989) Naunyn-Schmiede- 
berg’s Arch. Pharmacol. 339. 348-353. 
[42] Laychock. S.G, (1983) Mol. Cell. Endocrinol. 32, 157-170. 
[43] Arkhammar. P., Nilsson. T.. Welsh, M.. Welsh, N. and Bcrggrcn, 
P.-O. (l989! Biochem. J. 264, 307-215. 
[44] Rozcnyurt, E. (1956) Science 234, 161-166. 
[45] Kikkawa, U., Kishimoto, A. and Nishizuka. Y. (1939) Annu. 
Rev. Biochem. 58, 31-44. 
[46] Sjtiholm, A. (19Yl) FEBS Lett. 294, ‘757-260. 
90 
